French Pharmaceutical BaillyCreat Donates Medicines During its New Products Launch in Cambodia

Cambodia Investment Review

French pharmaceutical pioneer Bailly Creat which has been distributing its products in the Kingdom for nearly four decades is expanding its market share by introducing more of its medicines in Cambodia this year.

On Wednesday, October 26, the company through its distribution partner Zuellig Pharma, one of the largest healthcare services groups in Asia, will announce the release of Ibuprofen, Desloratadine, and Amoxicillin + Clavunic acid.

Marketing a wide range of products in Cambodia for more than 40 years

Patrick Choay, PCSA Group’s CEO, which owns Bailly Creat since 1996, is visiting the Kingdom to launch its new products and carry out its donation initiatives. The company will donate some of its medicines to Cambodia’s Red Cross and The Samdech Techo Voluntary Youth Doctor Association (TYDA), to help the country and its citizens with its medical needs.

Speaking during the launch ceremony, Choay stated that: “Bailly-Creat has been marketing a wide range of products in Cambodia for more than 40 years, medicines that respect European quality standards. We are optimistic that our collaboration with Zuellig Pharma will be long-lasting and a prolific one, not just for us, but for the people of Cambodia as well.”

“We are honored to be able to enrich our offer with the products we present to you today. These new medicines are now available at Zuellig Pharma to meet your prescription needs, and for dispensing in pharmacies,” he added.

Patrick Choay, an independent French pharmaceutical group, also owns CCD Laboratory which is at the core of women’s health for 50 years, GoménolLaboratory manufactures and produces cosmetics and food supplements, and Prodimed designs and manufactures disposable medical and surgical equipment and IUDs. With a strong workforce of 300 employees, it actively promotes its medicines globally.

Medicines that are at par with European quality standards

Bailly Laboratory that has started in 1901, and Creat Laboratory in 1972. The merge between Bailly Laboratory and Creat Laboratory has been acted in 2002. Bailly Creat is known for its expertise in the formulation, manufacture, and production of oral solid drug products and food supplements in dry form.

Backed by strong research and development programs, Bailly Creat produces and distributes its generic products in more than thirty countries.

In Cambodia, the company has been marketing a wide range of medicines that are at par with European quality standards. These medicines were patronized in Cambodia, hence the company believes that it is appropriate to return the favor by utilizing initiatives that will help many Cambodians treat their illnesses through the help of scientifically proven effective medicines.

Telegram Channel

Cambodia's best investment news & views direct into your Telegram account.


Related Posts